All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On April 30, 2020, a new pharmaceutical form of daratumumab (dara) was granted a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).1 This decision extends the market authorization of dara for the treatment of patients with multiple myeloma (MM) to include dara as a solution for subcutaneous (SC) injection (1,800 mg in 15 ml vial) into the abdomen.
This decision was shortly followed by the U.S. Food and Drug Administration (FDA) approval of dara and hyaluronidase-fihj for SC administration on May 1, 2020. The recommended dosing schedule is 1,800 mg dara plus 30,000 units hyaluronidase administered SC into the abdomen over ~3–5 minutes.2
The new formulation is recommended by the EMA CHMP, and approved by the FDA, for the following indications:
The EMA CHMP positive opinion also recommends dara-SC for adult patients with NDMM eligible for auto-SCT in combination with bortezomib, thalidomide and dexamethasone (VTd).
The COLUMBA trial (NCT03277105) was a pivotal study in the establishment of dara-SC and uncovered that dara-SC was non-inferior to intravenous administration. Patients reported an improved experience with dara-SC, with fewer infusion related reactions . The MM Hub previously provided an article summarizing the key points from the COLUMBA trial, as presented at the 2019 Annual American Society of Clinical Oncology (ASCO) Meeting—read it here. The MM Hub also reviewed the results from the phase II PLEIADES trial (NCT03412565), which investigated the efficacy and safety of dara-SC when combined with standard MM regimens, such as VMP, in both NDMM and RRMM.
EMA. Darzalex. https://www.ema.europa.eu/en/medicines/human/summaries-opinion/darzalex-1. Published 2020. Accessed May 01, 2020.
US FDA. FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma | FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-daratumumab-and-hyaluronidase-fihj-multiple-myeloma. Published 2020. Accessed May 4, 2020.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox